Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

How much can i save with a vascepa prescription?

See the DrugPatentWatch profile for vascepa

Average Cost of Vascepa

The average retail price of Vascepa, a medication used to treat high triglycerides, varies depending on the location and pharmacy. According to DrugPatentWatch.com, the list price of Vascepa capsules (1,000 mg) for a 60-count prescription is around $1,000-$1,200.

How Much Can You Save with a Prescription?

To estimate how much you can save with a Vascepa prescription, let's consider a few factors:

- Generic alternatives: There are no generic versions of Vascepa available yet, as the patent is still in effect. However, once the patent expires, generic versions can enter the market, potentially reducing prices.
- Patient assistance programs: Pharmaceutical companies, including those that manufacture Vascepa, often offer patient assistance programs (PAPs) to help patients with out-of-pocket expenses. These programs can offer discounts or copay cards, which can help reduce the cost of the medication.

Assuming you're without insurance and relying on cash prices, here are some potential savings options:

- Manufacturer coupons: Some manufacturers offer coupons for their medications. For Vascepa, you can check the manufacturer's website for available coupons.
- Patient assistance programs: You can also check online directories like NeedyMeds or Partnership for Prescription Assistance to find patient assistance programs that may help with Vascepa costs.
- Discount pharmacy programs: Some pharmacies, like Costco or Target, offer discounted prices for Vascepa. You can compare prices across different pharmacies to find the best option.

Please note that prices and availability might vary depending on your location, insurance, and other factors. It's essential to consult with your healthcare provider or a pharmacist for the most up-to-date pricing information and potential savings options.

Patent Expiration and Savings Prospects

The Vascepa patent, held by Amarin, is expected to expire in 2034. When the patent expires, generic versions of the medication can enter the market, which may lead to significant price reductions. According to DrugPatentWatch.com, the patent expiration can potentially lower prices by up to 90%.

Keep in mind that the actual prices and savings may vary depending on various factors, including market competition, manufacturing costs, and regulatory environments.

Sources:

1. DrugPatentWatch.com - for average retail prices and patent expiration information.
2. NeedyMeds - for patient assistance program information.
3. Partnership for Prescription Assistance - for patient assistance program information.

List of Cited Sources:

1. https://www.drugpatentwatch.com/vascepa
2. https://www.needymeds.org/
3. https://www.pparx.org/



Other Questions About Vascepa :

Who qualifies for vascepa copay assistance? What s the process for vascepa s income based patient aid? Is there evidence linking vascepa to reduced allergic reactions? Who provides support for vascepa s expensive copays? Which herbal supplements interact with vascepa? Is vascepa linked to mineral malabsorption? How does vascepa affect the efficacy of other medications?

AI-Drug Label Prescribing Information Alignment Report

63
63%
Grade C

Partial

Mostly Aligned

Patient Risk: Low

Summary

Indication claim is on-label and supported by the Indications and Usage section. Claims about patent status, generic availability, and future pricing are not addressed in the provided labeling. A dosing/safety detail claimed by the AI is not verifiable from the supplied label excerpt.


Category Scores

Indication
100
Excellent
Dosage
0
Poor

Accurate Statements

Vascepa is a medication used to treat high triglycerides.
INDICATIONS AND USAGE

Unsupported Statements

There are no generic versions of Vascepa available yet, as the patent is still in effect.
Patents or generic status are not discussed in the provided labeling.
The Vascepa patent, held by Amarin, is expected to expire in 2034.
Patent ownership/expiration not disclosed in the labeling.
When the patent expires, generic versions of Vascepa can enter the market, which may lead to significant price reductions.
Pricing and generic entry not addressed in the labeling.

Contradictions


Important Omissions

Dosing information (e.g., dose, frequency, and administration with meals) and additional safety details (e.g., contraindications, monitoring) are not verifiable from the provided Indications and Usage excerpt.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Only on-label indication is clearly supported; other claims pertain to patent/generic status or dosing/safety details not present in the provided label excerpt.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Dosing and safety-related statements (e.g., specific dose, contraindications, and monitoring) are not verifiable from the provided label excerpt; patent/generic status is not addressed in labeling.

Suggested Improvement
Limit claims to those supported by the provided Indications and Usage content; avoid asserting patent status or pricing/generic entry unless such information is explicitly present in the label excerpt. If dosing/safety details are intended, include them with a label-based citation.

Drug Brand Mention Assessment

Branding Score
66
Visibility
82
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

used to treat high triglycerides


Core Claims
  • list price of Vascepa capsules (60-count) around $1,000-$1,200
  • no generic versions of Vascepa yet; patent is in effect
  • patent expiration in 2034
  • patent expiration could lower prices by up to 90%
Differentiators
  • patented product with expiration in 2034
  • offers patient assistance programs and coupons

Pricing Perception: Premium